Standard Biotools (LAB) Capital Expenditures Growth (1y) (2011 - 2026)
Standard Biotools (LAB) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.02 Bn | 179.73 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 132.07 Bn | 129.19 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 111.38 Bn | 102.16 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 68.98 Bn | 67.53 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 48.32 Bn | 44.65 Bn | 1.29 Bn | 15.89% |
| 6 | Dexcom | 28.91 Bn | 27.80 Bn | 750.30 Mn | -11.95% |
| 7 | GE HealthCare Technologies | 28.83 Bn | 26.55 Bn | 1.98 Bn | 106.98% |
| 8 | Smith & Nephew | 28.10 Bn | 27.52 Bn | - | - |
| 9 | Koninklijke Philips | 24.30 Bn | 21.26 Bn | 2.01 Bn | -32.73% |
| 10 | Standard Biotools | 302.10 Mn | -153.08 Mn | 11.31 Mn | -93.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.69% |
| Dec 31, 2025 | 122.67% |
| Sep 30, 2025 | -100.97% |
| Jun 30, 2025 | -523.69% |
| Mar 31, 2025 | 547.12% |
| Dec 31, 2024 | -14.75% |
| Sep 30, 2024 | 449.50% |
| Jun 30, 2024 | -193.20% |
| Mar 31, 2024 | -22.67% |
| Dec 31, 2023 | -464.64% |
| Sep 30, 2023 | -28.40% |
| Jun 30, 2023 | -10.66% |
| Mar 31, 2023 | 16.36% |
| Dec 31, 2022 | 51.00% |
| Sep 30, 2022 | -90.13% |
| Jun 30, 2022 | -91.55% |
| Mar 31, 2022 | -87.46% |
| Dec 31, 2021 | -95.33% |
| Sep 30, 2021 | 3,676.11% |
| Jun 30, 2021 | 1,630.89% |